Familial fatal insomnia (FFI)
About
FFI is a hereditary prion disease caused by a point mutation at codon 178 of the PRNP gene (D178N) combined with a homozygote for methionine (Met/Met) at codon 129. This mutation causes the three-dimensional conformation of the cellular prion protein (PrP) to fold abnormally into the pathogenic prion protein (PrP). Selective damage to the ventroanterior and dorsomedial nuclei of the thalamus (responsible for sleep-wake regulation) results in severe atrophy of the thalamus. The treatment dilemma is extremely serious: ①PrP does not contain nucleic acid and cannot be dealt with antiviral strategies;② It has strong tolerance to routine autoclave and ultraviolet light;③ No confirmed PrP inhibitors have entered clinical trials. stage.
Features & Symptoms
- Progressive complete loss of sleep
- Rapid cognitive decline
- Movement disorders and autonomic nervous disorders
- No effective symptomatic means
Treatment Options
| Treatment | Description | Stage | Price Range |
|---|---|---|---|
| PRNP gene ASO therapy + prion protein stabilization experimental drug | Two cutting-edge strategies: antisense oligonucleotides target PRNP gene expression and reduce the production of normal PrP; small molecule compounds (such as quinacrine derivatives) aim to stabilize the normal three-dimensional conformation of PrP and prevent abnormal folding. | 临床前/Phase I规划 | $500K - $1.2M/年 |
Prognosis
Death 7-36 months after onset
Additional Notes
Notes: Genetic testing recommendations: People with a family history should be tested for the D178N mutation in the PRNP gene, which is highly related to FFI; Sleep management: There is currently no effective method to reverse insomnia, and palliative care should be the main focus, and sedative drugs can be tried to improve sleep quality; Autonomic nerve function monitoring: Symptoms of autonomic nerve disorders such as abnormal temperature regulation, tachycardia and hypertension need to be closely monitored; clinical trial enrollment: There are currently no open clinical trials, which can focus on the research progress of anti-prion compounds (such as PRN100); genetic counseling: Children of PRNP mutation carriers have a 50% genetic risk, so genetic counseling is recommended.; Exclusive service commitment: The platform will allocate a dedicated medical team to each patient to assist in dismantling and properly deploying the following precautions throughout the process. When cross-state and cross-border diagnosis and treatment projects or drugs are involved, the platform will make overall arrangements for the entire docking; for disabled and semi-disabled patient groups, the platform will provide rush-free alternative solutions (including remote consultation, door-to-door sampling, direct drug delivery in the cold chain, etc.), to ensure that patients can get the same high-quality diagnosis and treatment resources without having to travel in person.; Research phase: Preclinical research. Prognosis: Death 7-36 months after onset.
Frequently Asked Questions
What is Familial fatal insomnia (FFI)?
FFI is a hereditary prion disease caused by a point mutation at codon 178 of the PRNP gene (D178N) combined with a homozygote for methionine (Met/Met) at codon 129. This mutation causes the three-dimensional conformation of the cellular prion protein (PrP) to fold abnormally into the pathogenic prion protein (PrP). Selective damage to the ventroanterior and dorsomedial nuclei of the thalamus (responsible for sleep-wake regulation) results in severe atrophy of the thalamus. The treatment dilemma is extremely serious: ①PrP does not contain nucleic acid and cannot be dealt with antiviral strategies;② It has strong tolerance to routine autoclave and ultraviolet light;③ No confirmed PrP inhibitors have entered clinical trials. stage.
What are the symptoms of Familial fatal insomnia (FFI)?
Progressive complete loss of sleep,Rapid cognitive decline,Movement disorders and autonomic nervous disorders,No effective symptomatic means
How is Familial fatal insomnia (FFI) treated?
PRNP gene ASO therapy + prion protein stabilization experimental drug: Two cutting-edge strategies: antisense oligonucleotides target PRNP gene expression and reduce the production of normal PrP; small molecule compounds (such as quinacrine derivatives) aim to stabilize the normal three-dimensional conformation of PrP and prevent abnormal folding.
What is the prognosis for Familial fatal insomnia (FFI)?
Death 7-36 months after onset